General Information of Drug (ID: DMTK9M6)

Drug Name
PMID28454500-Compound-57 Drug Info
Cross-matching ID
PubChem CID
135315519
TTD Drug ID
DMTK9M6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Naphthalene derivative 1 DMWLPEB N. A. N. A. Patented [1]
PMID28454500-Compound-58 DMDEHYR N. A. N. A. Patented [1]
PMID28454500-Compound-60 DM1I9JC N. A. N. A. Patented [1]
PMID28454500-Compound-59 DMQWPSF N. A. N. A. Patented [1]
3-phenyl propanoic derivative 3 DM5GKS6 N. A. N. A. Patented [1]
1,2,3,4-tetrahydroisoquinoline derivative 1 DMW5DC1 N. A. N. A. Patented [1]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Omaveloxolone DMLMNFX Friedreich's ataxia 8A03.10 Approved [2]
CXA10 DMM7Z6K Focal segmental glomerulosclerosis MF8Y Phase 2 [3]
SFX-01 DMAQW9M Breast cancer 2C60-2C65 Phase 2 [4]
ABT-RTA-408 DM9Y1XB Non-small-cell lung cancer 2C25.Y Phase 2 [5]
OT-551 DMTNOXQ Ocular inflammation 9C61.24 Phase 2 [6]
OT551 DMHKIOF Age-related macular degeneration 9B75.0 Phase 2 [7]
HPP971 DMZXG7Q Non-alcoholic steatohepatitis DB92.1 Phase 1 [8]
PMID28454500-Compound-8 DM6BQFA N. A. N. A. Patented [1]
Pyrazino[2,1-a]isoquinolin derivative 4 DMKTNBC N. A. N. A. Patented [1]
PMID28454500-Compound-36 DM5RZWG N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) TTGIZLN KEAP1_HUMAN-NF2L2_HUMAN Modulator [1]
Nuclear factor erythroid 2-related factor 2 (Nrf2) TTA6ZN2 NF2L2_HUMAN Inhibitor [1]

References

1 Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
4 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
5 National Cancer Institute Drug Dictionary (drug id 756624).
6 New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
7 Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325.
8 Clinical pipeline report, company report or official report of vTv Therapeutics.